Compass Therapeutics, Inc. Common Stock (CMPX) Stock
NASDAQ · CMPX
1.12
Fundamentals
Market cap
$203.50M
Price / Earnings ratio
-2.8x
Price / Sales ratio
N/A
Price / Book ratio
1.2x
Return on assets
-35.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Stocktwits
CMPX Plunge Wipes Out $104M After FDA Demands Fresh Trial For Cancer Drug — Wedbush Sees Another 19% Downside
NeutralCMPXSeptember 22, 2026
StocktwitsNeutral
CMPX Plunge Wipes Out $104M After FDA Demands Fresh Trial For Cancer Drug — Wedbush Sees Another 19% Downside
CMPX

MarketBeat
Compass Therapeutics Eyes FDA Path After Tovecimig Trial Win
NeutralCMPXJune 8, 2026
MarketBeatNeutral
Compass Therapeutics Eyes FDA Path After Tovecimig Trial Win
CMPX

The Motley Fool
Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing
NeutralCMPXMarch 2, 2026
The Motley FoolNeutral
Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing
CMPX

Zacks Investment Research
Is Compass Therapeutics, Inc. (CMPX) Outperforming Other Medical Stocks This Year?
NeutralCMPXFebruary 17, 2026
Zacks Investment ResearchNeutral
Is Compass Therapeutics, Inc. (CMPX) Outperforming Other Medical Stocks This Year?
CMPX
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral1
Buy5
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
0000
Debt & Balance Sheet
Total assets
Total liabilities
2025
264M174M87M0
Revenue to Profit
2025$0.0
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-66.5M
Net incomeEarnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

Stocktwits
CMPX Plunge Wipes Out $104M After FDA Demands Fresh Trial For Cancer Drug — Wedbush Sees Another 19% Downside
NeutralCMPXSeptember 22, 2026
StocktwitsNeutral
CMPX Plunge Wipes Out $104M After FDA Demands Fresh Trial For Cancer Drug — Wedbush Sees Another 19% Downside
CMPX

MarketBeat
Compass Therapeutics Eyes FDA Path After Tovecimig Trial Win
NeutralCMPXJune 8, 2026
MarketBeatNeutral
Compass Therapeutics Eyes FDA Path After Tovecimig Trial Win
CMPX

The Motley Fool
Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing
NeutralCMPXMarch 2, 2026
The Motley FoolNeutral
Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing
CMPX

Zacks Investment Research
Is Compass Therapeutics, Inc. (CMPX) Outperforming Other Medical Stocks This Year?
NeutralCMPXFebruary 17, 2026
Zacks Investment ResearchNeutral
Is Compass Therapeutics, Inc. (CMPX) Outperforming Other Medical Stocks This Year?
CMPX

Zacks Investment Research
Wall Street Analysts See an 113.73% Upside in Compass Therapeutics, Inc. (CMPX): Can the Stock Really Move This High?
NeutralCMPXJanuary 27, 2026
Zacks Investment ResearchNeutral
Wall Street Analysts See an 113.73% Upside in Compass Therapeutics, Inc. (CMPX): Can the Stock Really Move This High?
CMPX

Zacks Investment Research
Are Medical Stocks Lagging Compass Therapeutics, Inc. (CMPX) This Year?
NeutralCMPXDecember 19, 2025
Zacks Investment ResearchNeutral
Are Medical Stocks Lagging Compass Therapeutics, Inc. (CMPX) This Year?
CMPX

Zacks Investment Research
Wall Street Analysts Think Compass Therapeutics, Inc. (CMPX) Could Surge 134.14%: Read This Before Placing a Bet
NeutralCMPXDecember 12, 2025
Zacks Investment ResearchNeutral
Wall Street Analysts Think Compass Therapeutics, Inc. (CMPX) Could Surge 134.14%: Read This Before Placing a Bet
CMPX

Zacks Investment Research
Here's Why Compass Therapeutics, Inc. (CMPX) is a Great Momentum Stock to Buy
NeutralCMPXDecember 8, 2025
Zacks Investment ResearchNeutral
Here's Why Compass Therapeutics, Inc. (CMPX) is a Great Momentum Stock to Buy
CMPX

Zacks Investment Research
2025's Top 3 Breakout Stocks for Active Traders: Don't Miss Out!
NeutralCMPXNovember 20, 2025
Zacks Investment ResearchNeutral
2025's Top 3 Breakout Stocks for Active Traders: Don't Miss Out!
CMPX

InvestorPlace
3 Penny Stocks With the Power to 10X Your $1K Investment
NeutralCMPXMarch 24, 2024
InvestorPlaceNeutral
3 Penny Stocks With the Power to 10X Your $1K Investment
CMPX
About Compass Therapeutics, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees39
CEODr. Thomas J. Schuetz M.D., Ph.D.
IPO DateApr 5, 2021
HeadquartersBoston, MA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Thomas J. Schuetz M.D., Ph.D. | CEO & Vice Chairman | 1961 |
| Mr. Barry Shin J.D., M.B.A. | Chief Financial Officer | 1972 |
| Mr. Jonathan E. Anderman J.D. | Senior VP, General Counsel & Corporate Secretary | 1983 |
| Mr. Neil L. Lerner CPA | Senior VP & Chief Accounting Officer | 1967 |
| Mr. Bing Gong Ph.D. | Chief Scientific Officer | 1976 |
| Anna Gifford | Senior Manager of Communications & Chief of Staff | — |
| Ms. Karin Herrera B.A. | Senior VP & Head of Clinical Operations | — |
| Dr. James Kranz Ph.D. | VP and Head of Chemistry Manufacturing & Controls | — |
| Dr. Cynthia A. Sirard M.D., Ph.D. | Chief Medical Officer | 1970 |
| Mr. Arjun Prasad M.B.A., M.P.H. | Chief Commercial Officer | 1978 |
Fundamentals
Valuation
Market cap$203.50M
Price-to-sales ratioN/A
Price-to-book value1.23
Price-earnings ratio-2.80
Return on Equity-40.00%
Return on SalesN/A
Return on Assets-35.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-0.39
Income Statement
Average volume4,248,046
EBITDA$-66.70M
1 year high (52w)$6.88
1 year low (52w)$1.10
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
6 Wall Street Analyst Ratings
BUY
83% Buy
17% Hold
0% Sell
Target price
$5.83
Est return
416.22%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -20.4 | -11.7 | ||||||||||
| 2022 | -50.0 | +20.8 | -31.8 | +0.0 | +108.9 | -9.2 | -1.9 | +4.2 | -21.4 | +23.9 | +20.2 | +9.3 |
| 2023 | -22.3 | -5.0 | -12.3 | -5.9 | -7.1 | +7.4 | -8.0 | -13.1 | -17.2 | -6.7 | -6.8 | -7.7 |
| 2024 | -12.2 | +42.4 | +4.2 | -21.7 | -10.2 | -26.5 | +8.4 | +58.0 | +21.9 | -13.7 | -4.1 | -12.7 |
| 2025 | +130.0 | -5.8 | -30.4 | -17.0 | +15.4 | +20.9 | +15.1 | +18.3 | +2.0 | +11.3 | +55.1 | -1.6 |
| 2026 | +23.8 | -13.3 | -6.9 | -67.4 | +21.4 | -1.4 | -12.4 | +26.5 | -51.1 |



